Bristol Myers’ next-gen immunology med busts Amgen’s Otezla in head-to-head study. Is a showdown coming?

In an immunology market packed with blockbuster biologics, Bristol Myers Squibb hopes that its oral drug for milder cases could carve out a lucrative foothold. Now, with its eyes set on busting Amgen’s Otezla, the drugmaker is rolling out full data from a pair of late-stage studies that bode well...

Click to view original post